https://www.clinicaltrialsarena.com/news/bms-sotyktu-psoriasis-trial/
BMS' Sotyktu shows consistent safety profile in psoriasis trial
Feb 17, 2025 - BMS has reported results from the POETYK PSO trial of its drug candidate Sotyktu (deucravacitinib) for plaque psoriasis.
consistent safetybmsshowsprofilepsoriasis
https://www.biospace.com/press-releases/neurocrine-biosciences-publishes-analysis-showing-long-term-efficacy-and-a-consistent-safety-profile-of-ingrezza-valbenazine-capsules-in-older-adults-with-tardive-dyskinesia-in-the-journal-of-clinical-psychiatry
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety...
neurocrine bioscienceslong termconsistent safetypublishesanalysis